Multiple Signalling Transduction Mechanisms Differentially Coupled to Somatostatin Receptor Subtypes: a Current View.
Author(s)
Cervia, Davide
Nunn, Caroline
Bagnoli, Paola
Date Issued
2005
Type
Article
Abstract
Somatostatin (SRIF) is a cyclic peptide widely distributed throughout the body with important physiological effects (mostly inhibitory) on several organ systems. SRIF may act as a neurohormone, neurotransmitter, neuromodulator or as a local factor, and exhibits potent antiproliferative activity. SRIF effects have formed the basis for the clinical use of SRIF analogues in the treatment of endocrine tumours, acromegaly and gastrointestinal disorders. Several data suggest that SRIF may also be a therapeutic target in a number of different diseases.
The binding of SRIF to its five G-protein coupled receptors leads to modulation of multiple transduction pathways, including adenylyl cyclase, guanylyl cyclase, phospholipase C, K+ and Ca2+ channels, phospholipase A2, nitric oxide, Na+/H+ exchanger, protein phosphatases and MAP kinases. The diversity of the transduction pathways reflects the pleiotropic actions of SRIF. However, our current understanding depicts a rather complicated picture and conflicting results have also been reported. Data are mostly based on in vitro experiments, and parallels with the real in vivo conditions are not so obvious. Due to the clinical relevance of the SRIF system, the elucidation of the intracellular role of endogenous SRIF receptors may offer new therapeutic perspectives. These will enable development of specific pharmacological signalling modulators which can be incorporated into the therapeutic arsenal.
The present review represents a detailed and exhaustive summary which covers the latest advances in the transduction pathways of SRIF receptors.
Additional information
L'articolo รจ disponibile sul sito dell'editore http://www.benthamscience.com/index.htm
Citation
Cervia, D., Nunn, C., Bagnoli, P. 2005. Multiple Signalling Transduction Mechanisms Differentially Coupled to Somatostatin Receptor Subtypes: a Current View. "Current Enzyme Inhibition" 1(3): 265-279
File(s)![Thumbnail Image]()
Name
Cervia et al-CEI 2005 1.pdf
Size
16.09 KB
Format
Adobe PDF
Checksum (MD5)
dfa25f05e7a202217bb960dd3bb6d089